Pharmacokinetics of bupivacaine enantiomers in sheep: Influence of dosage regimen and study design
Tóm tắt
Bupivacaine is used as a racemate. In previous studies the mean total body clearance ofR(+)-bupivacaine was found to be greater thanS(−)-bupivacaine by 65% after iv bolus dose of separate enantiomers and by 20% after iv infusion to steady state of racemate. The present studies were performed to determine whether different study designs using different iv dosage regimens could influence the pharmacokinetic parameters determined for either bupivacaine enantiomer. rac-Bupivacaine·HCl was administered iv to 6 adult Merino ewes by bolus, brief infusion, and prolonged infusion. Arterial blood concentrations ofR(+)- andS(−)-bupivacaine were measured by enantioselective HPLC. These regimens consistently produced lower arterial blood concentrations ofR(+)-bupivacaine thanS(−)-bupivacaine due toR(+)-bupivacaine having a greater initial dilution volume by 16 (95%CI=3–29)%, volume of distribution at steady state equilibrium by 32 (95%CI=17–32)% and mean total body clearance by 28 (95%CI=21–35)%. The slow half-life ofR(+)-bupivacaine, however, was found to be 15 (95%CI=0–31)% longer than that ofS(−)-bupivacaine. The difference between enantiomers in mean total body clearance thus was similar to the previous study based upon infusion to steady state of rac-bupivacaine. Differences in pharmacokinetics attributable to the dosage regimen consisted of a greater mean total body clearance forR(+)-bupivacaine along with a smaller terminal half life with the bolus regimen and a longer half-life ofS(−)-bupivacaine after prolonged infusion. Differences in pharmacokinetics between the bupivacaine enantiomers occurred consistently in both distribution and clearance but the magnitude of the effect was less than 50% in each case. Systematic differences in pharmacokinetics associated with the dosage regimen were found mainly in terminal half-life. Dosage regimen, thus, was found to influence the pharmacokinetic results found experimentally and is therefore a significant variable in its own right.
Tài liệu tham khảo
J. X. Mazoit, C. L. A. Berdeaux, J. L. Gerard, and R. Froidevaux. Pharmacokinetics of lidocaine after short and prolonged infusions in conscious dogs.Anesth. Analg. 67:961–966 (1988).
G. T. Tucker and L. E. Mather. Physicochemical properties, absorption and disposition of local anesthetics. In M. J. Cousins and P. O. Bridenbaugh (eds.),Neural Blockade in Clinical Anesthesia and Management of Pain (2nd Ed.), JB Lippincott, Philadelphia, 1988, pp. 47–110.
L. E. Mather. Disposition of mepivacaine and bupivacaine enantiomers in sheep.Br. J. Anaesth. 67:239–246 (1991).
A. J. Rutten, L. E. Mather, and C. F. McLean. Cardiovascular effects and regional clearances of intravenous bupivacaine in sheep: enantiomeric analysis.Br. J. Anaesth. 67:247–256 (1991).
A. J. Rutten, L. E. Mather, C. F. McLean, and C. Nancarrow. Tissue distribution of bupivacaine enantiomers in sheep.Chirality 5:485–491 (1993).
G. Aberg. Toxicological and local anaesthetic effects of optically active isomers of two local anaesthetic compounds.Acta Pharmacol. Toxicol. 31:273–386 (1972).
F. Vanhoutte, J. Vereeke, N. Vebeke, and E. Carmeliet. Stereoselective effects of the enantiomers of bupivacaine on the electrophysiological properties of the guinea-pig papillary muscle.Br. J. Pharmacol. 103:1275–1281 (1991).
D. D. Denson, M. M. Behbehani, and R. V. Gregg. Enantiomer-specific effects of an intravenously administered arrhythmogenic dose of bupivacaine on neurons of the nucleus tractus solitarius and the cardiovascular system in the anesthetized rat.Reg. Anesth. 17:311–316 (1992).
J. X. Mazoit, O. Boico, and K. Samii. Myocardial uptake of bupivacaine: II. Pharmacokinetics and pharmacodynamics of bupivacaine enantiomers in the isolated perfused rabbit heart.Anesth. Analg. 77:477–482 (1993).
C. Nancarrow, W. B. Runciman, L. E. Mather, R. N. Upton, and J. L. Plummer. The influence of acidosis on the distribution of lidocaine and bupivacaine into the myocardium and brain of the sheep.Anesth. Analg. 66:925–935 (1987).
A. J. Rutten, L. E. Mather, C. Nancarrow, P. A. Sloan, and C. F. McLean. Cardiovascular effects and regional clearances of intravenous ropivacaine in sheep.Anesth. Analg. 70:577–582 (1990).
C. Nancarrow, A. J. Rutten, W. B. Runciman, L. E. Mather, R. J. Carapetis, C. F. McLean, and S. F. Hipkins. Myocardial and cerebral drug concentrations and the mechanisms of death after fatal intravenous doses of lidocaine, bupivacaine and ropivacaine in the sheep.Anesth. Analg. 67:276–283 (1989).
A. J. Rutten, C. Nancarrow, L. E. Mather, A. H. Ilsley, W. B. Runciman, and R. N. Upton. Hemodynamic and central nervous system effects of intravenous bolus doses of lidocaine, bupivacaine and ropivacaine in sheep.Anesth. Analg. 69:291–299 (1989).
Y. F. Huang, R. N., Upton, and W. B. Runciman. IV bolus administration of subconvulsive doses of lignocaine to conscious sheep: Relationship between myocardial pharmacokinetics and pharmacodynamics.Br. J. Anaesth. 70:556–561 (1993).
A. J. Rutten, L. E. Mather, J. L. Plummer, and E. C. Henning. Postoperative course of plasma protein binding of lignocaine, ropivacaine and bupivacaine in sheep.J. Pharm. Pharmacol. 44:355–358 (1992).
B. Bruguerolle and M. Prat. Circadian phase-dependent protein and tissular binding of three local anesthetics (bupivacaine, etidocaine, and mepivacaine) in mice: A possible mechanism of their chronotoxicokinetics?Chronobiol-Int. 9:448–452 (1992).
G. T. Tucker, L. Wiklund, A. Berlin-Whalen, and L. E. Mather. Hepatic clearance of local anesthetics in man.J. Pharmacokin. Biopharm. 5:111–122 (1977).
L. Wiklund. Human hepatic blood flow and its relation to systemic circulation during intravenous infusion of bupivacaine or etidocaine.Acta Anaesth. Scand. 21:189–199 (1977).
A. G. L. Burn, A. D. van der Meer, J. W. van Kleef, P. W. M. Zeijlmans, and K. Groen. Pharmacokinetics of the enantiomers of bupivacaine following intravenous administration of the racemate.Br. J. Clin. Pharmac. 38:125–129 (1994).
S. Bower and C. J. Hull. Comparative pharmacokinetics of fentanyl and alfentanil.Br. J. Anaesth. 54:871–877 (1982).
J. R. Varvel, S. L. Shafer, S. S. Hwang, P. A. Coen, and D. R. Stanski. Absorption characteristics of transdermally administered fentanyl.Anesthesiology 70:928–934 (1989).
M. O. Karlsson and L. B. Sheiner. The importance of modeling interoccasion variability in population pharmacokinetic analyses.J. Pharmacokin. Biopharm. 21:735–750 (1993).
G. T. Tucker and L. E. Mather. Pharmacokinetics of local anaesthetic agents.Br. J. Anaesth. 47:213–224 (1975).
A. G. Burm, J. W. van Kleef, N. P. Vermeulen, G. Olthof, D. D. Breimer, and J. Spierdijk. Pharmacokinetics of lidocaine and bupivacaine following subarachnoid administration in surgical patients: simultaneous investigation of absorption and disposition kinetics using stable isotopes.Anesthesiology 69:584–592 (1988).
B. T. Veering, A. G. Burm, A. A. Vletter, R. A. van den Hoeven, and J. Spierdijk. The effect of age on systemic absorption and systemic disposition of bupivacaine after subarachnoid administration.Anesthesiology 74:250–257 (1991).
K. Pihlajamaki, J. Kanto, R. Lindberg, M. Karanko, and P. Kiiholma. Extradural administration of bupivacaine: pharmacokinetics and metabolism in pregnant and nonpregnant women.Br. J. Anaesth. 64:556–562 (1990).
P. H. Rosenberg, P. Pere, R. Hekali, and M. Touminen. Plasma concentrations of bupivacaine and two of its metabolites during continuous interscalene brachial plexus block.Br. J. Anaesth. 66:25–30 (1991).
W. B. Runciman, A. H. Ilsley, L. E. Mather, R. Carapetis, and M. M. Rao. A sheep preparation for studying the interaction of regional blood flow and drug disposition: I. Physiological profile.Br. J. Anaesth. 56:1015–1028 (1984).